AIDS
Conditions
Interventions
80mg Group:Placebo:2, 80mg Albuvirtide: 6
160mg Group 1:Placebo:2, 160mg Albuvirtide: 6
320mg Group 3:320mg Albuvirtide: 6
20mg Group:Placebo:2, 20mg Albuvirtide: 6
320mg Group 1:Placebo:2, 320mg Albuvirtide: 8
160mg Group 2:160mg Albuvirtide: 6
Sponsors
Beijing You’an Hospital affiliated to Capital medical university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. HIV antibody test is positive or possessing HIV medical card; 2. Male and female patients aged 18 to 45 years old; 3. CD4+ cell count>=250/ul, virus load>=5000copies/ml; 4. Body weight >=40 kg and BMI is between 18 to 27 kg/m2; No severe hepatic or renal dysfunction, albumin and other routine health check is normal; 5. Patients are non-users of cigarette or alcohol, or agree stopping smoking and drinking during the trial; 6. Patients did not receive any anti-hepatitis virus medicine. Patients should not receive anti-HIV medicine or have stopped over half year.7.Patients voluntarily signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with acute HIV infection; 2. ALT< twice of upper limit or Creatinine is abnormally high or other biochemical test results are abnormal; 3. Patients who received anti-HIV medicine within half year before screening; 4. Patients with severe opportunistic infection or tumors; 5. Patient is allergic constitution or allergic to more than two drugs or food; 6. Patients with severe digestive, hematological, metabolic, neurological, mental disorder, or any inherited disease; 7. Pregnant or lactating women or women who won't take contraceptive intervention during the trial; 8. Patients with fever within 3 days; 9. Patients with other issues that is not eligible to this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lab test (hematology, biochemistry, CD4+ cell count, virus loads, urine analysis); | — |
Countries
China
Contacts
Public ContactHao Wu
Outcome results
None listed